Sanofi's Dr Jack Prior detailed a data maturity framework for biologics manufacturing, while FDA and Gilead panelists debated risk-based AI validation.
Bob Buhlmann
Advertisement
Bob Buhlmann is executive director and head of digital quality at Gilead Sciences.
Articles by Bob Buhlmann
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Merck and Kelun’s Sac-TMT Extends Survival by Nearly 7 Months in Pretreated Endometrial Cancer
2
Treasury Proposes Adding Biotech to Outbound Investment Restrictions Under COINS Act
3
BMS Reports Death in Phase 1 Zolacabtagene Autoleucel MS Study
4
BioNTech’s HER2 ADC Hits Phase 3 Goal, but Companies See Limited Benefit
5